RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of RGX-019 FOR IMMEDIATE